Rabeprazole (Molecule of the Month for July 2013)
Aciphex, Pariet
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names Aciphex and Pariet.
Rabeprazole is a prodrug (metabolized by the cytochrome P450 (or CYP450)) - in the acid environment of the parietal cells it turns into active sulphenamide form associated with cysteine of H+, K+ATPase (proton pump). Rabeprazole inhibits (partly reversibly) H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Rabeprazole has anti Helicobacter pylori activity (MIC 4-16 mg/ml) and shows synergistic activity with some antibiotics. Rabeprazole has been demonstrated to be effective in patients with pathological hypersecretory activity (incl. Zollinger-Ellison Syndrome).
Formal Chemical Name (IUPAC)
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
References
click on the picture of Rabeprazole above to interact
with the 3D model of the
Rabeprazole structure
(this will open a new browser window)
C18 H21 N3 O3 S
Update by Karl Harrison
(Molecule of the Month for
July 2013
)
All the images on this web site are are made available with a Creative Commons Attribution license and so can be used as long as the attribution © Karl Harrison 3DChem.com is written with the image. High resolution images and illustrations are available on request.